Evidence map›Paper›PMID 37375823›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Enhancement of Scaffold In Vivo Biodegradability for Bone Regeneration Using P28 Peptide Formulations.

Farah Alwani Azaman, Margaret E Brennan Fournet, Suzina Sheikh Ab Hamid, Muhamad Syahrul Fitri Zawawi, Valdemiro Amaro da Silva Junior, Declan M Devine

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Farah Alwani AzamanPRISM Research Institute, Technological University of the Shannon (TUS), N37 HD68 Athlone, Ireland.ORCID 0000-0003-0155-5350
Margaret E Brennan FournetPRISM Research Institute, Technological University of the Shannon (TUS), N37 HD68 Athlone, Ireland.ORCID 0000-0002-9811-1715
Suzina Sheikh Ab HamidTissue Bank, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), 16150 Kota Bharu, Malaysia.
Muhamad Syahrul Fitri ZawawiTissue Bank, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), 16150 Kota Bharu, Malaysia.ORCID 0000-0001-8905-4782
Valdemiro Amaro da Silva JuniorDepartamento de Medicina Veterinária, Universidade Federal Rural de Pernambuco, Recife 52171-900, Brazil.
Declan M DevinePRISM Research Institute, Technological University of the Shannon (TUS), N37 HD68 Athlone, Ireland.ORCID 0000-0002-1364-5583

Funding

Enterprise Ireland commercialisation fund CF-2016-0600-P
6 · The paper itself

Abstract

The field of bone tissue engineering has shown a great variety of bone graft substitute materials under development to date, with the aim to reconstruct new bone tissue while maintaining characteristics close to the native bone. Currently, insufficient scaffold degradation remains the critical limitation for the success of tailoring the bone formation turnover rate. This study examines novel scaffold formulations to improve the degradation rate in vivo, utilising chitosan (CS), hydroxyapatite (HAp) and fluorapatite (FAp) at different ratios. Previously, the P28 peptide was reported to present similar, if not better performance in new bone production to its native protein, bone morphogenetic protein-2 (BMP-2), in promoting osteogenesis in vivo. Therefore, various P28 concentrations were incorporated into the CS/HAp/FAp scaffolds for implantation in vivo. H&E staining shows minimal scaffold traces in most of the defects induced after eight weeks, showing the enhanced biodegradability of the scaffolds in vivo. The HE stain highlighted the thickened periosteum indicating a new bone formation in the scaffolds, where CS/HAp/FAp/P28 75 µg and CS/HAp/FAp/P28 150 µg showed the cortical and trabecular thickening. CS/HAp/FAp 1:1 P28 150 µg scaffolds showed a higher intensity of calcein green label with the absence of xylenol orange label, which indicates that mineralisation and remodelling was not ongoing four days prior to sacrifice. Conversely, double labelling was observed in the CS/HAp/FAp 1:1 P28 25 µg and CS/HAp/FAp/P28 75 µg, which indicates continued mineralisation at days ten and four prior to sacrifice. Based on the HE and fluorochrome label, CS/HAp/FAp 1:1 with P28 peptides presented a consistent positive osteoinduction following the implantation in the femoral condyle defects. These results show the ability of this tailored formulation to improve the scaffold degradation for bone regeneration and present a cost-effective alternative to BMP-2.

Indexed as

bone regenerationbone tissue engineeringchitosanosteogenesisscaffold degradation

Identifiers

PMID37375823
PMCPMC10304976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.